Proof-of-Concept and Safety of the Anti-FcRn Antibody Rozanolixizumab in Patients with Moderate-to-Severe Generalized Myasthenia Gravis (GMG): A Phase 2a Study

被引：0
|
作者：
Bril, Vera [1 ,2 ,3 ]
Benatar, Michael [4 ]
Brock, Melissa [5 ]
Greve, Bernhard [5 ]
Kiessling, Peter [5 ]
Woltering, Franz [5 ]
Van den Bergh, Peter [6 ]
机构：
[1] Toronto Gen Hosp, Ellen & Martin Prosserman Ctr Neuromuscular Dis, Toronto, ON, Canada
[2] Univ Toronto, Div Neurol, Toronto, ON, Canada
[3] Imam Abdulrahman Bin Faisal Univ, Inst Res & Med Consultat, Dammam, Saudi Arabia
[4] Univ Miami, Miami, FL USA
[5] UCB Pharma, Raleigh, NC USA
[6] Univ Louvain, Univ Hosp St Luc, Dept Neurol, Neuromuscular Reference Ctr, Brussels, Belgium
来源：
NEUROLOGY | 2019年 / 92卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
S43.001
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial
    Klein, Friederike
    [J]. FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2022, 90 (09) : 386 - +
  • [2] Response to rozanolixizumab in patients with generalized myasthenia gravis (gMG) from the Phase 3 MycarinG study
    Vissing, J.
    Druzdz, A.
    Grosskreutz, J.
    Habib, A.
    Mantegazza, R.
    Utsugisawa, K.
    Vu, T.
    Grimson, F.
    Lejdstrom, R. Beau
    Pulido-Valdeolivas, I.
    Tarancon, T.
    Bril, V.
    [J]. NEUROMUSCULAR DISORDERS, 2023, 33 : S178 - S179
  • [3] Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis A Phase 2 Randomized Control Trial
    Bril, Vera
    Benatar, Michael
    Andersen, Henning
    Vissing, John
    Brock, Melissa
    Greve, Bernhard
    Kiessling, Peter
    Woltering, Franz
    Griffin, Laura
    van den Bergh, Peter
    [J]. NEUROLOGY, 2021, 96 (06) : E853 - E865
  • [4] SERUM AUTOANTIBODY LOWERING BY THE ANTI-FCRN MONOCLONAL ANTIBODY, NIPOCALIMAB, CORRELATES WITH CLINICAL IMPROVEMENT IN GENERALIZED MYASTHENIA GRAVIS PATIENTS
    Guptill, Jeffrey
    Antozzi, Carlo
    Bril, Vera
    Gamez, Josep
    Meuth, Sven G.
    Nowak, Richard
    Quan, Dianna
    Sevilla, Teresa
    Ling, Leona
    Zhu, Yaowei
    Karcher, Keith
    Ramchandren, Sindhu
    Sun, Hong
    [J]. MUSCLE & NERVE, 2022, 65 : S4 - S4
  • [5] Serum Autoantibody Lowering by the Anti-FcRn Monoclonal Antibody, Nipocalimab, Correlates With Clinical Improvement in Generalized Myasthenia Gravis Patients
    Ramchandren, Sindhu
    Guptill, Jeff
    Antozzi, Carlo
    Bril, Vera
    Gamez, Josep
    Meuth, Sven
    Nowak, Richard
    Quan, Dianna
    Mantecon, Maria Teresa Sevilla
    Ling, Leona
    Zhu, Yaowei
    Karcher, Keith
    Sun, Hong
    [J]. NEUROLOGY, 2022, 99 (23) : S35 - S37
  • [6] Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study
    GomezMancilla, Baltazar
    Meriggioli, Matthew N.
    Genge, Angela
    Roubenoff, Ronenn
    Espie, Pascal
    Dupuy, Cyrielle
    Hartmann, Nicole
    Pezous, Nicole
    Kinhikar, Arvind
    Tichy, Mia
    Dionne, Annie
    Vissing, John
    Andersen, Henning
    Schoser, Benedikt
    Meisel, Andreas
    Jordan, Berit
    Devlikamova, Farida
    Poverennova, Irina
    Stuchevskaya, Fatima
    Lin, Thy-Sheng
    Rush, James S.
    Gergely, Peter
    [J]. JOURNAL OF CLINICAL NEUROSCIENCE, 2024, 119 : 76 - 84
  • [7] Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia
    Robak, Tadeusz
    Kazmierczak, Maciej
    Jarque, Isidro
    Musteata, Vasile
    Trelinski, Jacek
    Cooper, Nichola
    Kiessling, Peter
    Massow, Ute
    Woltering, Franz
    Snipes, Rose
    Ke, Juan
    Langdon, Grant
    Haier, Birgit
    Bussel, James B.
    Jolles, Stephen
    [J]. BLOOD, 2019, 134
  • [8] Phase II, Multiple-Dose Study of Anti-FcRn Antibody, Rozanolixizumab (UCB7665), in Patients with Primary Immune Thrombocytopenia: Interim Analysis
    Robak, Tadeusz
    Jarque, Isidro
    Musteata, Vasile
    Kiessling, Peter
    Massow, Ute
    Higginson, James
    Snipes, Rose
    Jolles, Stephen
    [J]. BLOOD, 2017, 130
  • [9] Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study
    Taylor, Peter C.
    Schett, Georg
    Huizinga, Tom W. J.
    Wang, Qingmin
    Ibrahim, Fowzia
    Zhou, Bei
    Liva, Sophia G.
    Shaik, Jafar Sadik B.
    Xiong, Yuan
    Leu, Jocelyn H.
    Panchakshari, Rohit A.
    Loza, Matthew J.
    Ma, Keying
    Dhatt, Harman
    Rojo Cella, Ricardo
    Karyekar, Chetan S.
    Cuff, Carolyn A.
    Gao, Sheng
    Fei, Kaiyin
    [J]. RMD OPEN, 2024, 10 (02):
  • [10] Safety of Amlitelimab in a Phase 2a Clinical Trial of Patients With Moderate-to-Severe Atopic Dermatitis
    Weidinger, Stephan
    Cork, Michael
    Reich, Adam
    Bieber, Thomas
    Gilbert, Sally
    Quaratino, Sonia
    Wilson, Rosamund
    Porter-Brown, Ben
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB221 - AB221
12345